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Despite the important role of cannabinoid CB1 receptors (CB1R) in brain development, little is known about their status during
adolescence, a critical period for both the development of psychosis and for initiation to substance abuse. In the present study,
we assessed the ontogeny of CB1R in adolescent and adult rats in vivo using positron emission tomography with [18F]MK-9470.
Analysis of covariance (ANCOVA) to control for body weight that would potentially inﬂuence [18F]MK-9470 values between the
twogroupsrevealedamaineﬀectofage(F(1,109) = 5.0,P = 0.02)on[18F]MK-9470absolutebinding(calculatedaspercentageof
injected dose) with adult estimated marginal means being higher compared to adolescents amongst 11 brain regions. This ﬁnding
was conﬁrmed using in vitro autoradiography with [3H]CP55,940 (F(10,99) = 140.1, P<0.0001). This ontogenetic pattern,
suggesting increase of CB1R during the transition from adolescence to adulthood, is the opposite of most other neuroreceptor
systems undergoing pruning during this period.
1.Introduction
The endocannabinoid system is a lipid signalling system [1]
that appeared early in evolution [2]. It consists of at least
two G-protein-coupled cannabinoid receptors CB1 and CB2
(CB1R and CB2R) [3], their intrinsic ligands (endocannabi-
noids) such as N-arachidonoyl ethanolamine (anandamide,
AEA) [4] and 2-arachidonoyl glycerol (2-AG) [5], and their
associated proteins involved in synthesis, transport, and
degradation [6].
The CB1R, which mediates the psychoactive eﬀects of
marijuana, is widely expressed and is considered one of the
most abundant G-protein-coupled receptors in the brain. In
the central nervous system, endocannabinoids are released
from postsynaptic sites and, by activation of the presy-
naptically located CB1R[ 7], inhibit the release of several
neurotransmitters such as GABA, glutamate [8], dopamine,
and acetylcholine [9]. In vitro immunohistochemical [10]
and autoradiography [11] studies in rats have shown that
the CB1R is highly expressed in the basal ganglia (lateral
caudate-putamen, globus pallidus, entopeduncular nucleus,
and substantia nigra pars reticulata), cerebellum (molecular
layer), and hippocampus (CA1, CA3, and dentate gyrus
molecular layer). Moderate levels are found throughout the
cortical regions, whereas low levels are observed in the
brainstem (midbrain, pons) and spinal cord.
TheCB1Rhasbeenshowntobeinvolvedinvariousphys-
iological functions like nociception [12], control of move-
ment [13], memory [14], neuroendocrine regulation [15],
brain development, and maturation [16, 17]. Biochemical
and functional alterations of CB1R have been shown to be
implicated in the pathophysiology of distinct neurological2 International Journal of Molecular Imaging
and psychiatric disorders [18] including schizophrenia [19–
21]. It is known that cannabis and its derivatives can trigger
psychotic-like symptoms in normal individuals [22], and
numerous epidemiological studies have demonstrated that
consuming cannabis during adolescence (particularly early
adolescence) constitutes a risk factor for schizophrenia onset
later in life [23–25].
Adolescence is a critical developmental period during the
transition from childhood to adulthood. The ages associated
with adolescence are commonly considered in humans to
be approximately 12 to 20–25 years of age and postnatal
day (PND) 28–55 in rodents [26]. The adolescent brain
undergoesbothprogressive andregressivechangesproviding
the biological basis for the unique adolescent behaviors and
their associated changes during maturation to adulthood. At
the cellular level, these changes correspond to the marked
overproduction of axon and synapses in early puberty and
rapid pruning in late adolescence [27]. To date, most devel-
opmental studies of the cannabinoid system [28–31]h a v e
focused on the embryonic and early postnatal stages. In vitro
autoradiographic studies have reported a ﬁvefold increase
in CB1R density in the brain during postnatal development
[32]. CB1R capacity in the striatum was doubled between
PND 14 and 21. Signiﬁcant increases in CB1Rd e n s i t y
appeared regionally in the developing brain until PND 21
[32]o rP N D3 0[ 33], and the maximum adult level was
reached at PND 60 [32]. In contrast, Rodriguez de Fonseca
et al. [33] reported slight decreases in binding between PND
30 and 40 and adulthood (PND 70).
Recently, the development of new eﬃcient radiotracers
has enabled the study of CB1R in vivo using positron
emission tomography (PET). Burns et al. [34] demonstrated
that the selective, high-aﬃnity inverse agonist for the CB1R,
named [18F]MK-9470 had the potential to be a valuable tool
for the in vivo study of CB1R biology and pharmacology.
Several in vivo preclinical [35–41] and clinical studies [42–
45] have used this compound successfully.
We have recently reported higher levels of dopamine
D1 and D2 receptors [46], both serotonin 5HT1A receptor
binding and mRNA expression [47], and GABAA receptor
binding [48] in adolescent rats (PND 39) compared to
adults (PND 70), that is, in accordance with the regressive
elimination of synapses and receptors that occurs during the
transitionfromadolescencetoadulthood[27].Inthepresent
study, we have undertaken two objectives: ﬁrst, to demon-
strate the feasibility of imaging CB1R in vivo in adolescence
and adulthood using small animal PET with [18F]MK-
9470; second, to compare the level of expression/regional
distribution of CB1R in adolescent and adult rats obtained
in vivo with PET and in vitro with autoradiography using
[3H]CP55,940. The aim was to test the hypothesis whether
CB1R pruning occurs during the transition from adolescence
to adulthood as it has been indicated for other neuroreceptor
systems.
2.MaterialsandMethods
2.1. Radiochemical Synthesis of [18F]MK-9470. CB1Ri m a g -
ing was performed in all animals using the radioligand
[18F]MK-9470 (N-[2-(3-cyanophenyl)-3-(4-(2-[18F]ﬂuor-
oethoxy)phenyl)-1-methylpropyl]-2-(5-methyl-2-pyridy-
loxy)-2-methylpropanamide),ahighspeciﬁcity,high-aﬃnity
inverse agonist at the CB1R. The precursor for radiotracer
synthesis and the authentic [19F]MK-9470 standard were
obtained from MERCK Research labs (West Point, Pa,
USA). Radiolabelling was performed using a two-step
semiautomated procedure following the method outlined by
Burns et al. [34] with some modiﬁcations. In the ﬁrst step,
2-Bromo-1[18F]ﬂuoroethane ([18F]BrFE) was synthesised
using a Nuclear Interface FDG synthesizer (GE Medical
System). 18F-Fluoroalkylation of the MK-9470 precursor
was then manually carried out using Cs2CO3 as a base. An
aliquot of [18F]BrFE was added, and [18F]MK-9470 was
o b t a i n e di nu pt o8 %o v e r a l ly i e l d( n o tc o r r e c t e df o rd e c a y )
after high-performance liquid chromatography (HPLC) and
Sep-Pak puriﬁcation. [18F]MK-9470 product was conﬁrmed
by coinjection with the [19F]MK-9470 standard. The ﬁnal
product obtained had a radiochemical purity > 95% and
speciﬁc activity averaging 6000Ci/mmole (222GBq/µmole).
2.2. Animals. Male Wistar rats were obtained from the
Animal Resource Centre Pty. Ltd (Perth, Australia) and were
housed in polyethylene boxes with wire lids (489 × 343 ×
240mm) in groups of two-three per cage. All handling of
animals and procedures was carried out in accordance with
the guidelines established by the Animal Care and Ethics
CommitteeattheAustralianNuclearScienceandTechnology
Organisation (ANSTO). The animals were kept at a constant
temperature of 22 ± 2◦C on a 12–12h light-dark cycle
with lights on at 9 am and were handled during the seven
days preceding the experiment. Food and water were freely
available.
The adult cohort consisted of 6 rats with body weights
ranging between 381 ± 22g at 10 weeks of age (PND 70–
72), and the adolescent cohort consisted of 6 rats with body
weights ranging between 148 ± 22g at 7 weeks of age (PND
35–37).
2.3. In Vivo PET/CT with [18F]MK-9470
2.3.1. Acquisition and Reconstruction. Animals were fasted
for at least 6 hours before the start of the experiment. PET
imaging with [18F]MK-9470 was performed with a preclini-
cal PET/CT Inveon (Siemens) system [49]. Anaesthesia was
induced by exposing rats to 4% isoﬂurane in oxygen and
then maintained by reducing the ratio to 1.5–2.5% for the
durationofthestudies.Isoﬂuraneanesthesiahasbeenshown
not to have any signiﬁcant eﬀects on absolute [18F]MK-9470
binding as compared to control conditions [36]. The eyes
were coated with a lubricating eye ointment (Allergan Inc.,
Ireland). Body temperature was maintained by a heating
pad set at 38◦C and monitored rectally. Heart rate (333.2
± 25.9beats/min), respiratory rate (41.6 ± 9.2cycles/min),
and saturation in oxygen (>95%) were measured with a
pulse oximeter (Starr, Life Sciences Corp, USA). We also
monitored the respiratory rate under the CT part of the
scanner with a pressure sensor connected to a computer
(Biovet, m2m imaging crop, USA). After anaesthesia andInternational Journal of Molecular Imaging 3
placing of the animal in the scanner with the help of laser
guidance, a catheter was placed in a lateral tail vein of the
rat and connected to an infusion pump (Harvard Apparatus,
USA). A 60min PET scan was started at the same time of
the start of the one-minute injection of [18F]MK-9470 at a
constant tracer mass (65.2 ± 1.5pmoles). A 15min CT scan
was systematically performed after the PET scan. Activity
volumes were reconstructed with an iterative reconstruction
(OSEM/MAP)[50]including attenuation and scattercorrec-
tion, achieving a reconstructed spatial resolution of 1.5mm.
2.3.2. Data Analysis. A previously developed magnetic-
resonance-imaging- (MRI-)based rat brain atlas was coreg-
istered to the PET volume, using the CT information of the
skull (Anatomist/BrainVisa, V3.1.4, http://brainvisa.info/).
In detail, all PET acquisitions (12 animals) were coregistered
with their respective CT (see Figure 1). All CTs in the
adolescent cohort were manually/visually coregistered to
one adolescent CT (“adolescence reference CT”). The same
methodology was used in the adult group. Finally, the
“reference” CTs were manually/visually coregistered to the
MRI-based rat brain atlas encompassing eleven volumes of
interest (VOI) (Figure 2(a)). Transformation matrixes were
then created from the MRI-based rat brain atlas to each PET
image in each group.
Previous studies in rats with [18F]MK-9470 have used
the last 20min of a 60min acquisition period (40 to
60min) for quantiﬁcation purposes [35–37]. In this study,
we used percentage of injected dose (activity concentration
(MBq/mL) divided by injected dose (MBq)) of the last 20
minutes of acquisition (%ID40–60)a sa b s o l u t eC B 1R binding
measure.
2.4. In Vitro Autoradiography with [3H]CP55,940
2.4.1. Experiments. Twenty-four hours after in vivo imaging,
the animals (6 adolescents and 5 adults) were euthanized,
their brain was dissected, frozen in liquid nitrogen, and
stored at −80◦C. Coronal brain sections (16µm) were cut
with a cryostat and thaw-mounted onto microscope slides.
[3H]CP55,940 autoradiography was carried out based on
the method previously described in Dalton et al. [51]. All
sections were processed simultaneously to minimize exper-
imental variance. On the day of the experiment, sections
were taken out of the −80◦Cf r e e z e ra n da l l o w e dt oc o m e
to room temperature for approximately 60min or until dry.
Sections were preincubated for 30min at room temperature
in 50mM Tris-HCl (pH 7.4) containing 5% bovine serum
albumin (BSA) in order to equilibrate the tissue to the assay
conditions and remove any endogenous ligand. Radioligand
binding was measured using single-point saturation analysis
which provides a good estimate of receptor density. The Kd
ofratbrainCB1R has been evaluated at 5.2nM [11]. In order
to ensure saturation of CB1R, sections were then incubated
for 2h at room temperature in the same buﬀer as preincu-
bation with the addition of 10nM [3H]CP55,940 (speciﬁc
activity 139.6Ci/mmole, Perkin Elmer, USA). Nonspeciﬁc
binding was determined by incubating adjacent sections
in the presence of 10µM CP55,940. The concentration of
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Figure 1: Typical in vivo PET/CT scan images of an adolescent
(PND 35–37) and an adult (PND 70–72) Wistar rat in transversal
(left) and sagittal (right) planes. For illustration purpose, the
absolute binding intensity of [18F]MK-9470 to CB1R( % I D 40–60)
was increased (Anatomist/BrainVisa, V3.1.4, http://brainvisa.info/)
inordertoreﬂecttheresultsexpressedinestimatedmarginalmeans
of %ID40–60, that is, a higher CB1R absolute binding in adults com-
pared to adolescents.
[3H]CP55,940 was measured in 10µLa l i q u o t st a k e nf r o m
the incubation mixture. After the incubation, sections were
washedfor1hat4◦Cin50mMTris-HCl(pH7.4)containing
1% BSA, and a second wash was then carried out for 3h
in the same buﬀer at 4◦C. The third wash was in 50mM
Tris-HCl (pH 7.4) for 5min at 4◦C. Sections were then
dipped brieﬂy in ice cold distilled water and then dried.
Dried sections were apposed to Kodak Biomax MR ﬁlms,
together with autoradiographic tritium standards ([3H]
microscales from Amersham), in X-ray ﬁlm cassettes. Films
weredevelopedafter35daysusingKodakGBXdeveloperand
ﬁxed with Kodak GBX ﬁxer.
2.4.2. Data Analysis. Films were analysed using a computer-
assisted image analysis system, Multianalyst, connected to a
GS-690ImagingDensitometer(Bio-Rad,USA).Elevenbrain
regions of interest (ROI) were manually drawn with the help
of a stereotaxic atlas of the rat brain [52] and corresponded
to the 11 VOI analysed in vivo (Figure 4). Quantiﬁcation
of receptor binding in each brain region was performed
by measuring the average optical density in adjacent brain
sections. Nonspeciﬁc binding wassubtractedtototal binding
to give a value for speciﬁc binding. Optical density measure-
ments for speciﬁc binding were then converted into fmoles
of [3H]CP55,940 per mg of tissue equivalent (fmol/mg TE)
according to the calibration curve obtained from the [3H]-
labelled standards.
2.5. Statistical Analysis. Statistical tests were performed
using PASW Statistics (Version 18.0.0) and Graphpad Prism
(Version 5.04). Data were analysed for signiﬁcant outliers
(±2SD), and none were detected. The Kolmogorov-Smirnov
test was used to test normality of the data. Parametric tests
were used in subsequent analysis since data were normally
distributed. The mass and injected dose of [18F]MK-9470
between the adolescent and adult cohorts were compared
using unpaired Student’s t-tests. Pearson correlations were4 International Journal of Molecular Imaging
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Figure 2: (a) In vivo PET/CT images of [18F]MK-9470 binding (%ID40–60 ±SEM) at 5 diﬀerent coronal levels in the adolescent and the adult
rat brain. The MRI-based atlas of the rat brain with 11 VOI is shown on the right side of the image. (b) Histograms presenting the adjusted
absolute [18F]MK-9470 binding intensities (estimated marginal means of %ID40–60 ± SEM) in the adolescent compared to the adult cohort
in 11 VOI. Two-way ANCOVA (age × region) controlling for weight was used to assess statistical signiﬁcant diﬀerences in absolute [18F]MK-
9470 binding between adulthood and adolescence. Statistical analysis revealed that there was a signiﬁcant (#P<0.05 signiﬁcant main eﬀect)
increase in CB1R absolute binding (44.4% calculated over 11 VOI) in adulthood compared to adolescence. Abbreviations: Striat: striatum;
Frtl Cx: frontal cortex; Hipp: hippocampus; Thal: thalamus; Hypothal: hypothalamus; Amyg: amygdala; Sup Coll: superior colliculus; Cereb:
cerebellum.
used to examine the relationship between %ID40–60 and
body weight and between [18F]MK-9470 CB1R binding in
vivo and [3H]CP55,940 CB1R binding in vitro. Analysis of
covariance (ANCOVA) controlling for body weight was used
to determine if there was an eﬀect of age and/or region on
CB1R absolute binding measured in vivo. In vitro data were
analysed using two-way ANOVA (age × region) followed by
least signiﬁcant diﬀerence (LSD) tests. Signiﬁcance was set at
P ≤ 0.05.
3. Results
3.1.InVivoPETwith[18F]MK-9470. Adolescentratsshowed
the regional distribution that corresponds to the previously
published regional distribution of CB1R[ 11, 53], but adult
rats unexpectedly demonstrated a more uniform regional
distribution of the PET radioligand (Figures 1 and 2).
Cerebellum, striatum, cortical regions, and (moderately)
hippocampus showed higher in vivo CB1R absolute binding
compared to other brain regions. Regions known to have
fewer CB1R like the thalamus and especially the brainstem
(midbrain, pons) presented relatively high CB1Ra b s o l u t e
binding in vivo (Figure 2).
Time-activity curves (expressed in %ID40–60) showed
that [18F]MK-9470 entered the brain with a slow kinetic and
reached a peak at approximately 20min after-injection.
There were no statistically signiﬁcant diﬀerences in the
mass of [18F]MK-9470 injected between the adolescent and
a d u l tc o h o r t( m e a n± SEM: 64.8 ± 1.5pM and 66.2 ±
2.9pM, resp., t(10) = 0.73, P = 0.48). No statistical diﬀer-
ences were found in the injected doses (ID) (t(10) = 0.56,
P = 0.59)betweentheadolescents(8.22±2.07MBq)andthe
adults (7.02 ± 0.59MBq). Animal weights were found to be
signiﬁcantly diﬀerent (t(10) = 18.16, P<0.0001) between
adolescent (148 ± 9g) and adult animals (382 ± 9g),
and Pearson’s correlation showed that weight was strongly
and negatively correlated to %ID40–60 (r =− 0.921, P<
0.0001). Two-way ANCOVA (age × region) controlling for
weight showed a signiﬁcant main eﬀect of age (F(1,109) =
4.95, P = 0.028) with adults having higher CB1Ra b s o l u t e
binding compared to adolescents (+44.4% over 11 VOI)
(Figure 2(b)). A signiﬁcant eﬀect of region was also found
(F(10,109) = 2.41, P = 0.012).Nointeractionwasobserved
b e t w e e na g ea n dr e g i o n( F(10,109) = 0.84, P = 0.59).
Table 1 presents CB1R absolute binding levels in adolescents
and adults before (unadjusted values) and after controlling
for animal body weight (adjusted values).
3.2. In Vitro [3H]CP55,940 Autoradiography. Two-way
ANOVA (age × region) showed a statistically signiﬁcant
main eﬀect of age (F(1,99) = 17.323, P<0.0001) with the
adults having higher CB1R binding than the adolescentsInternational Journal of Molecular Imaging 5
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Figure 3: Time-activity kinetic curves of [18F]MK-9470 expressed in %ID40–60 ± SEM in 6 volumes of interest (VOI), in the adolescent
(n = 6) (dotted line in red) and the adult (n = 6) (plain line in blue) cohort. Note that adolescents’ kinetic curves appear higher compared
to adults’ kinetic curve because values are expressed as %ID40–60 not taking into account weight as covariate. Estimated marginal means of
%ID40–60 were evaluated in the ANCOVA and showed higher [18F]MK-9470 absolute binding in adults compared to adolescents.
(Figure 4). A signiﬁcant main eﬀect of region (F(10,99) =
140.1, P<0.0001) was also found. No interaction between
age and region (F(10,99) = 1.62, P = 0.113) was observed.
The signiﬁcant main eﬀect of age was further analysed by
LSD post hoc tests revealing that CB1R-speciﬁc binding was
signiﬁcantly higher in the adults compared to adolescents
in the frontal cortex (+23.4%; P = 0.024), the cortex
(+27.1%; P = 0.020), the hippocampus (+15.4%; 0.018),
and the cerebellum (+15.2%, P = 0.002) (Table 2 and
Figure 4).6 International Journal of Molecular Imaging
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Figure 4: (a) In vitro autoradiographies of total [18F]MK-9470 binding intensity in coronal sections in an adolescent and an adult rat brain.
The atlas of Paxinos and Watson [52] serves as a visual anatomical reference of the 11 brain regions analysed. (b) Histograms of the in vitro
speciﬁc binding intensities of [18F]MK-9470 (fmoles/mg TE ± SEM) in the adolescent compared to the adult rat brain. Eleven regions of
interest were analysed and assessed for statistical signiﬁcant diﬀerence between adolescence and adulthood with two-way ANOVA (age ×
region) followed by LSD post hoc tests (∗P<0.05; ∗∗P<0.01). Statistical analysis revealed a signiﬁcant main eﬀect (#P<0.05) of age
with adults having higher CB1R densities than adolescents. The frontal cortex, the cortex, the hippocampus, and the cerebellum showed a
statistically signiﬁcant increase in adults compared to adolescence in the post hoc analysis. Abbreviations: Striat: striatum; Frtl Cx: frontal
cortex; Hipp: hippocampus; Thal: thalamus; Hypothal: hypothalamus; Amyg: amygdala; Sup Coll: superior colliculus; Cereb: cerebellum.
Table 1: CB1 receptor in vivo binding levels ([18F]MK-9470) in adolescents and adults rats.
Adolescents Adults % change (adjusted)
Unadjusted Adjusted Unadjusted Adjusted
Striatum 0.86 ± 0.07 0.49 ± 0.07 0.38 ± 0.03 0.74 ± 0.07 50.3
Frontal cortex 0.83 ± 0.06 0.47 ± 0.07 0.38 ± 0.03 0.75 ± 0.07 59.8
Cortex 0.83 ± 0.07 0.47 ± 0.07 0.38 ± 0.03 0.74 ± 0.07 58.5
Hippocampus 0.83 ± 0.06 0.47 ± 0.07 0.38 ± 0.03 0.75 ± 0.07 59.9
Thalamus 0.86 ± 0.06 0.49 ± 0.07 0.37 ± 0.03 0.74 ± 0.07 49.1
Hypothalamus 0.86 ± 0.06 0.50 ± 0.07 0.40 ± 0.03 0.76 ± 0.07 52.0
Amygdala 0.81 ± 0.06 0.45 ± 0.07 0.36 ± 0.03 0.73 ± 0.07 63.1
Superior colliculus 0.97 ± 0.07 0.61 ± 0.07 0.42 ± 0.03 0.79 ± 0.07 29.2
Cerebellum 1.04 ± 0.09 0.68 ± 0.07 0.44 ± 0.03 0.80 ± 0.07 18.2
Midbrain 0.90 ± 0.06 0.54 ± 0.07 0.38 ± 0.02 0.75 ± 0.07 38.6
pons 0.95 ± 0.07 0.58 ± 0.07 0.39 ± 0.03 0.75 ± 0.07 29.0
Unadjusted values are mean %ID40–60 ±SEM; adjusted values are estimated marginal means %ID40–60 ±SEM.
Two-way ANCOVA controlling for weight was performed (n = 6p e rg r o u p ) .
Covariates appearing in the ANCOVA model are evaluated at the following values: weight = 264.9142.
3.3. Correlation between [18F]MK-9470 CB1RB i n d i n gI nV i v o
and[3H]CP55,940CB1 RBindingI nV itro. Correlationswere
not statistically signiﬁcant between absolute CB1R binding
evaluated with [18F]MK-9470 in vivo and speciﬁc CB1R
binding calculated with [3H]CP55,940 in vitro,( r = 0.1816,
P = 0.41).
4. Discussion
In the present study, we used two complementary techniques
to examine potential developmental diﬀerences in CB1R
binding in the brain of adolescent and adult rats. After
controlling for body weight, CB1R absolute binding mea-
sured in vivo with PET and [18F]MK-9470 was signiﬁcantly
higher in the adult animals compared to adolescents over
11 brain regions. This ﬁnding was conﬁrmed in vitro with
autoradiography and [3H]CP55,940.
Noteworthy, the percentage of increase observed in
the adult compared to the adolescent cohort with the 2
complementary techniques was not of the same magnitude
(44% in vivo versus 11% in vitro over the 11 regions of
interest), and no signiﬁcant correlation was found betweenInternational Journal of Molecular Imaging 7
Table 2: CB1 receptor in vitro binding levels ([3H]CP55,940) in adolescents and adults rats.
Adolescents Adults % change P value
Striatum 34.62 ± 2.18 39.13 ± 2.38 13.0 0.117
Frontal cortex 28.12 ± 2.21 34.68 ± 2.51 23.4 0.024
Cortex 25.02 ± 2.49 31.81 ± 1.86 27.1 0.020
Hippocampus 44.51 ± 2.03 51.36 ± 2.26 15.4 0.018
Thalamus 20.90 ± 1.41 20.70 ± 1.16 −0.9 0.946
Hypothalamus 38.46 ± 1.53 41.01 ± 2.40 6.6 0.376
Amygdala 30.41 ± 2.29 35.09 ± 3.62 15.4 0.106
Superior colliculus 28.58 ± 1.12 26.16 ± 2.93 −8.5 0.400
Cerebellum 59.89 ± 1.66 68.98 ± 2.23 15.2 0.002
Midbrain 5.86 ± 0.96 6.35 ± 0.51 8.4 0.864
Pons 6.12 ± 1.50 6.70 ± 0.92 9.5 0.840
Two-way ANOVA followed by LSD post hoc test.
Data expressed as mean fmol/mg TE ± SEM; n = 6p e rg r o u p .
the data obtained with the two techniques. The comparison
between in vitro and in vivo results (no correlation) and the
apparent discrepancies may relate to a number of factors.
Firstly, methodological issues of data analysis should be
considered. The percentage of injected dose (% ID) that we
used here gives an absolute index of binding in vivo. This
means that it reﬂects speciﬁc and nonspeciﬁc binding in the
brain,radioligandpresentinthebrainbloodcirculation,and
possible radioactive metabolites crossing the blood-brain
barrier. We did not calculate standardised uptake values
(absolute index normalising for weight) because it would
have biased our results as our two groups had signiﬁcantly
diﬀerent weight means. Also, the absence of a brain region
devoid of CB1R prevented us from implementing a sim-
pliﬁed reference tissue model. We chose to use an atlas-
based analysis of our data, with predeﬁned VOI, over a
statistical parametric mapping approach because we wanted
to compare the same regions with the in vivo and in
vitro methodologies. To our knowledge, the metabolism
of [18F]MK-9470 in the male (adult and adolescent) rat
brain has not been assessed; therefore, the presence of active
metabolites that cross the blood-brain barrier cannot be
ruled out. Indeed, a metabolite is likely to cross the blood-
brain barrier of adult female Wistar rats (Casteels et al.,
oral communication). Radiometabolites produced in adults
(but not in adolescents) could potentially cross the blood
brain barrier, aﬀect the %ID we calculated, and in turn
contribute to the uniform regional distribution of the PET
radioligand we observed in adults compared to adolescents
(Figures 1 and 2). Diﬀerences in radioligand present in
the brain blood circulation (e.g., diﬀerence in blood ﬂow)
between the adolescent and adult cohorts that would have
aﬀected our measures cannot be ruled out either. To be in
line with previous studies in rats with [18F]MK-9470 [35–
37], we have used the last 20min of a 60min acquisition
period (40 to 60min) for quantiﬁcation purposes. A recent
study however indicated that the distribution volume (VT)
of [18F]MK-9470 as quantitative outcome evaluated by full
kinetic modelling was reasonably correlated with standard-
iseduptakevaluesbetween60and80min(Casteelsetal.,oral
communication, 2011). Longer acquisitions periods (at least
80min)infuturestudiesusingthisradioligandwouldensure
that equilibrium is reached.
The second factor that could explain discrepancies
between in vitro and in vivo results is the drug phenotype.
Indeed, [18F]MK-9470 is an inverse agonist at CB1R[ 34],
whereas [3H]CP55,940 is an agonist at both CB1Ra n d
CB2R[ 54, 55]. The concentration of CB2R in the rat brain
is supposed to be small in comparison to CB1R[ 3, 56,
57]. Thus, [3H]CP55,940 binding in the brain will mainly
reﬂect CB1R. Inverse agonists will preferentially bind to
receptors uncoupled from their G-protein, whereas agonists
will preferentially bind to receptors that are coupled to their
G-protein [58]. This means that in vivo we would have
preferentially bound CB1R uncoupled to their G-protein,
whereasinvitrotheG-protein-coupledoneswouldhavebeen
targeted. In vitro assays typically reﬂect all receptors that are
availabletobindtoradioligand,whereasinvivo,onlyasubset
of these receptors are available to bind to radioligand since
some may be compartmentalised, some in a low aﬃnity state
and some occupied by endogenous ligand [59].
Finally, another factor aﬀecting the comparison between
in vitro and in vivo measures is the diﬀerence in concentra-
tion of the radioligand used. Theory of PET experiment is
based upon the injection of a radioligand at tracer concen-
tration that is not supposed to trigger any biological eﬀect.
Inordertomeetthisrequirement,theradioligandshouldnot
bindtomorethan5–10%ofthetotalreceptorsconcentration
(Bmax)[ 59]. Based on previously reported Bmax in rat brain
(0.5–1.1pmol/mg prot) [11], we calculated that the mass
of ligand needed to be approximately 0.1–0.7nmoles. On
the other hand, quantitative in vitro autoradiography studies
need saturation of the available binding sites (at least 3
times greater than the Kd). Thus, by saturating a diﬀerent
proportion of receptors in vivo and in vitro,d i ﬀerential
outcomes must be cautiously interpreted.
Our main results, showing an increase in CB1Ri n
adults (PND 70–72) compared to adolescents (PND 35–
37) in vivo and in vitro, are in accordance with in vitro
studies that have looked at CB1R expression over time8 International Journal of Molecular Imaging
in development. Belue and collaborators [32]h a v ef o u n d
signiﬁcant regional increases in the numbers of CB1R( Bmax)
inthedevelopingratbrain(PND0,7,14,21,and60)usingin
vitro autoradiography with [3H]CP55,940. Although CB1R
density was not measured during adolescence, this study
suggested that CB1R binding continuously increased until
the maximum adult level was reached at PND 60. They
observed that cortical regions (mainly posterior cortex) and
hippocampus showed a statistically signiﬁcant increase in
binding between PND 21 and PND 60 [32]. According to
the authors, the increase in CB1R could be an indication
of either an increased diﬀerentiation of neurones into
cells harbouring CB1R or an induction of the expression
of CB1R in cells already diﬀerentiated. Another in vitro
study using the same radioligand ([3H]CP55,940) showed
that CB1Rs are transiently expressed in white matter areas
during embryonic and early postnatal periods, progressively
“shift” to their adult localization at PND 30, and increase
between PND 30 and adulthood in the hippocampus,
nucleus accumbens, and cerebral cortex [53]. In addition,
Ellgren et al. [60]r e p o r t e da ni n c r e a s ei nC B 1Rp r o t e i n
expression in the nucleus accumbens shell and no changes in
prefrontal cortex between mid-(PND 38) and late-(PND 49)
adolescence.
In humans, an in vitro study found an increase in CB1R
density between children/infant age (n = 5, 3 months
to 8 years old) and adults (n = 5, 22 to 73 years old)
in frontal cortex, hippocampus CA1 and DG, caudate
putamen,globuspallidus,andcerebellum[61].Interestingly,
a recent PET study using [18F]MK-9470 found an increase in
CB1R binding in the basal ganglia, lateral temporal cortex,
and limbic system of aged female but not male humans
[62]. Another PET study using [11C]OMAR in healthy
males showed an age-associated decline in CB1Rv o l u m eo f
distribution that was signiﬁcant in globus pallidus only [63].
To allow comparison with other studies from our group [46,
51], we chose to evaluate the ontogeny of CB1R in adolescent
and adult male rodents. Recent experiments have shown that
female Wistar rats presented a high ∼35–39% intersubject
variability in CB1R binding evaluated as [18F]MK-9470
standard uptake values between 60 and 80 minutes (Casteels
et al., oral communication, 2011). Intersubject variability in
our study with males only was of 17% in the adult group
and 18% in the adolescent group. Future in vivo animal
studies looking at the ontogeny of CB1R in female rats as
well as during aging would help in clarifying the relation-
ships between gender, aging, and the endocannabinoid sys-
tem Figure 3.
In the mammalian brain, synapses and receptors within
most regions are overproduced and eliminated during two
phases of life. The ﬁrst one occurs just before birth, after
completion of the brain innervation, and witnesses the
apoptosis (programmed cell death) of 50% of neurones in
order to increase eﬃciency of synaptic transmission [64, 65].
The second one occurs during the periadolescence period
withatremendousoverproductionofsynapsesandreceptors
followed by their progressive elimination or pruning [27].
This pattern of expression—overproduction followed by
elimination—is shared among mammalian brains and part
of a fundamental developmental strategy called “functional
validation” [27]. Teicher et al. [66]r e p o r t e da no v e r p r o d u c -
tion of D1 and D2 from PND 25 to 40 followed by a pruning
to reach adulthood [66]. We have recently reported higher
levels of dopamine D1 and D2 receptors [46], both serotonin
5HT1A receptor binding and mRNA expression [47], and
GABAA receptor binding [48] in adolescent rats (PND 39)
compared to adults (PND 70) that is in line with the regres-
sive elimination of synapses and receptors that occurs during
the transition from adolescence to adulthood. In contrast,
the results of the present study indicate that CB1Rs are
not undergoing a dramatic elimination between adolescence
(PND 35–37) and adulthood (PND 70–72) and continue to
increase, at least until PND 70–72. Our study does not rule
out the possibility that the CB1Rs are undergoing pruning at
alaterdevelopmental“aging”stage.Possibleexplanationsfor
the observed upregulation in adult rats can be hypothesised.
Since a homeostatic and modulatory role is attributed to
endocannabinoids [57], the CB1R upregulation could be
related to a compensation of functional losses in other
monaminergic or GABAergic systems. In addition, changes
in CB1R may reﬂect changes in endocannabinoid markers
such as AEA and 2-AG. Limited information is available
regarding endogenous cannabinoid ligands levels during the
transition from adolescence to adulthood; however, a recent
study has shown an increase of AEA but not 2-AG levels
from early to late adolescence in the prefrontal cortex of
the rats [60]. Studies looking at the developmental proﬁle of
endocannabinoid ligands in diﬀerent brain regions and their
correlations with CB1R levels would help in elucidating the
developmental and morphogenic roles of this system during
the transition from adolescence to adulthood.
5. Conclusion
The present study demonstrated the feasibility of imaging
CB1R in vivo with PET and [18F]MK-9470 in adolescent
and adult rats. Our results suggest that CB1Rs are increased
during the transition from adolescence (PND 35–37) to
adulthood (PND 70–72), a pattern that is opposite of
most other neuroreceptor systems that have already started
undergoing pruning during this time window. Availability of
newradioligandssuchas[18F]MK-9470incombinationwith
PET would oﬀer a unique opportunity to gain insights into
the role of the endocannabinoid system during critical stages
of development using longitudinal and within-subjects
experimental designs and understand the consequences of
its alterations after pharmacological challenges as well as in
neurodevelopmental animal models of psychosis.
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